Key result
Selexipag was safely initiated and titrated in an outpatient setting for patients with pulmonary arterial hypertension, achieving a mean daily maintenance dose of 1,830 μg with no drug discontinuations.
Why the study?
To better understand the real-world approach to selexipag titration and establish individualized maintenance regimens in clinical practice outside clinical trial settings.
Does selexipag titration in a real-world outpatient setting achieve safe individualized dosing in patients with pulmonary arterial hypertension?
Observational (n=20)
No
Does selexipag titration in a real-world outpatient setting achieve safe individualized dosing in patients with pulmonary arterial hypertension?
Selexipag can be safely initiated, titrated, and transitioned in an outpatient setting to achieve individualized dosing regimens in real-world patients with pulmonary arterial hypertension.
Supports outpatient selexipag titration in PAH; leaves open need for randomized confirmation before practice change.
Selexipag is an oral selective prostacyclin-receptor agonist that was approved for use in patients with World Health Organisation (WHO) functional class II-III pulmonary arterial hypertension (PAH). Treatment with individualised doses of selexipag resulted in significant reductions in the composite end point of death or a complication related to PAH in the phase III GRIPHON (Prostacyclin [PGI2] Receptor Agonist In Pulmonary Arterial Hypertension) study. In order to better understand the real-world approach to selexipag titration and to establish the individualised maintenance regimens used in our centre, we performed this retrospective study of the first 20 patients prescribed selexipag. Baseline characteristics differed from the GRIPHON study, with more combination therapy and comorbidities at drug initiation. Maintenance doses were stratified as low-dose in 10% (n=2), medium-dose in 70% (n=14) and high-dose in 20% (n=4). This study highlights that selexipag can be safely initiated, titrated and transitioned in an outpatient setting to achieve an individualised dosing regimen.
No takes yet. Share an insight, caveat, or question.
Cullivan et al. (2021) conducted an observational in Pulmonary arterial hypertension (n=20). Selexipag was evaluated on Individualized maintenance dose achieved. Selexipag was safely initiated and titrated in an outpatient setting for patients with pulmonary arterial hypertension, achieving a mean daily maintenance dose of 1,830 μg with no drug discontinuations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: